Bernard Fox

Summary

Publications

  1. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"
    Paolo A Ascierto
    Istituto Nazionale Tumori, Fondazione G, Pascale, Naples, Italy
    J Transl Med 11:137. 2013
  2. pmc The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
    Paolo A Ascierto
    Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione G, Pascale, Napoli, Italy
    J Transl Med 11:54. 2013
  3. pmc Cancer classification using the Immunoscore: a worldwide task force
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, Paris, F 75006, France
    J Transl Med 10:205. 2012
  4. pmc Lean oncology: a new model for oncologists
    Vincenzo Montesarchio
    Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G, Pascale, Via Mariano Semmola, 80131, Naples, Italy
    J Transl Med 10:74. 2012
  5. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 10:83. 2012
  6. pmc The immune score as a new possible approach for the classification of cancer
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, 15 Rue de l Ecole de Medecine F 75006 Paris, France
    J Transl Med 10:1. 2012
  7. pmc Supporting the advancement of science: Open access publishing and the role of mandates
    Lisa Phelps
    BioMed Central, 236 Gray s Inn Road, Floor 6, London, WC1X 8HB, UK
    J Transl Med 10:13. 2012
  8. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  9. pmc SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery
    Davide Bedognetti
    Society for Immunotherapy of Cancer, Milwaukee, WI, USA
    J Transl Med 9:155. 2011
  10. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 9:32. 2011

Collaborators

Detail Information

Publications15

  1. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"
    Paolo A Ascierto
    Istituto Nazionale Tumori, Fondazione G, Pascale, Naples, Italy
    J Transl Med 11:137. 2013
    ....
  2. pmc The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
    Paolo A Ascierto
    Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione G, Pascale, Napoli, Italy
    J Transl Med 11:54. 2013
    ..The challenge will be to identify the individual immunoprofile of each patient and the consequent choice of optimal therapy or combination of therapies to be used...
  3. pmc Cancer classification using the Immunoscore: a worldwide task force
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, Paris, F 75006, France
    J Transl Med 10:205. 2012
    ..The results of this international validation may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune)...
  4. pmc Lean oncology: a new model for oncologists
    Vincenzo Montesarchio
    Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G, Pascale, Via Mariano Semmola, 80131, Naples, Italy
    J Transl Med 10:74. 2012
    ..Its main objective is the centrality of the patient...
  5. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 10:83. 2012
    ....
  6. pmc The immune score as a new possible approach for the classification of cancer
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, 15 Rue de l Ecole de Medecine F 75006 Paris, France
    J Transl Med 10:1. 2012
    ....
  7. pmc Supporting the advancement of science: Open access publishing and the role of mandates
    Lisa Phelps
    BioMed Central, 236 Gray s Inn Road, Floor 6, London, WC1X 8HB, UK
    J Transl Med 10:13. 2012
    ..Journal of Translational Medicine in affiliation with the Society for Immunotherapy of Cancer demonstrates how private and public organisations can work together for the advancement of science...
  8. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  9. pmc SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery
    Davide Bedognetti
    Society for Immunotherapy of Cancer, Milwaukee, WI, USA
    J Transl Med 9:155. 2011
    ..This organized collection of the most useful references, online resources and tools serves as a compass to guide discovery of biomarkers essential to advancing novel cancer immunotherapies...
  10. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 9:32. 2011
    ..Four topics of discussion were identified: New pathways in Melanoma, Biomarkers, Clinical Trials and New Molecules and Strategies...
  11. pmc A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
    Lisa H Butterfield
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA
    J Transl Med 6:81. 2008
    ..This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document...
  12. pmc Therapeutic T cells induce tumor-directed chemotaxis of innate immune cells through tumor-specific secretion of chemokines and stimulation of B16BL6 melanoma to secrete chemokines
    Hauke Winter
    Department of Surgery, LMU Munich, Klinikum Grosshadern 81377 Munich, Germany
    J Transl Med 5:56. 2007
    ..This led us to hypothesize that macrophages played a central role in tumor regression following T-cell transfer. Here, we sought to determine the factors responsible for the infiltration of macrophages at the tumor site...
  13. pmc Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology
    Hideaki Tahara
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    J Transl Med 7:45. 2009
    ..The institution of an interactive consortium for high throughput molecular monitoring of clinical trials with voluntary participation might provide cost-effective solutions...
  14. pmc Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response
    Dominik Ruttinger
    Department of Surgery, Grosshadern Medical Center, Ludwig Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
    J Transl Med 5:43. 2007
    ..This paper reports on the first clinical experience and evidence of an immune response in patients suffering from NSCLC...
  15. pmc Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects
    Ulf Petrausch
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, 4805 NE Glisan Street, Portland, OR 97213, USA
    Curr Mol Med 9:673-82. 2009
    ..Finally, we will describe possible ways to interfere with regulatory T cell-mediated immune suppression with the focus on recent pre-clinical and clinical findings...

Research Grants18

  1. Mechanisms That Regulate Tumor-Specific Immune Responses
    Bernard A Fox; Fiscal Year: 2010
    ..Here we propose to investigate strategies to further improve on these results and generate data that will pave-the-way for a series of new clinical trials for patients with advanced cancer. ..
  2. Exploiting Lymphopenia to Augment the Adoptive Immunotherapy of Melanoma Patients
    Bernard Fox; Fiscal Year: 2009
    ..Aim 3 will characterize the regulatory T cell population in the peripheral blood prior to and following induction of lymphopenia and reconstitution. ..
  3. Mechanisms That Regulate Tumor-Specific Immune Responses
    Bernard Fox; Fiscal Year: 2007
    ..3 and C.5 of our Preliminary studies to explore this question in Aim 3. ..
  4. Exploiting Lymphopenia to Augment the Adoptive Immunotherapy of Melanoma Patients
    Bernard Fox; Fiscal Year: 2007
    ..Aim 3 will characterize the regulatory T cell population in the peripheral blood prior to and following induction of lymphopenia and reconstitution. ..
  5. Mechanisms That Regulate Tumor-Specific Immune Responses
    Bernard Fox; Fiscal Year: 2006
    ..3 and C.5 of our Preliminary studies to explore this question in Aim 3. ..
  6. Exploiting Lymphopenia to Augment the Adoptive Immunotherapy of Melanoma Patients
    Bernard Fox; Fiscal Year: 2006
    ..Aim 3 will characterize the regulatory T cell population in the peripheral blood prior to and following induction of lymphopenia and reconstitution. ..
  7. Mechanisms That Regulate Tumor-Specific Immune Responses
    Bernard Fox; Fiscal Year: 2005
    ..3 and C.5 of our Preliminary studies to explore this question in Aim 3. ..
  8. Mechanisms That Regulate Tumor-Specific Immune Responses
    Bernard Fox; Fiscal Year: 2004
    ..3 and C.5 of our Preliminary studies to explore this question in Aim 3. ..
  9. Identify and amplify T cell effector mechanisms
    Bernard Fox; Fiscal Year: 2004
    ..If this innovative approach using novel immune activated pro-drug molecules is successful in these preclinical studies it could be rapidly translated into phase I clinical trials for patients with cancer. ..
  10. Mechanisms That Regulate Tumor-Specific Immune Responses
    Bernard Fox; Fiscal Year: 2003
    ..3 and C.5 of our Preliminary studies to explore this question in Aim 3. ..
  11. Identify and amplify T cell effector mechanisms
    Bernard Fox; Fiscal Year: 2003
    ..If this innovative approach using novel immune activated pro-drug molecules is successful in these preclinical studies it could be rapidly translated into phase I clinical trials for patients with cancer. ..
  12. Identify and amplify T cell effector mechanisms
    Bernard Fox; Fiscal Year: 2002
    ..If this innovative approach using novel immune activated pro-drug molecules is successful in these preclinical studies it could be rapidly translated into phase I clinical trials for patients with cancer. ..
  13. MECHANISMS THAT REGULATE TUMOR SPECIFIC IMMUNE RESPONSES
    Bernard Fox; Fiscal Year: 2002
    ..3) To develop in vivo strategies that promote the differentiation of tumor-specific T1 T cells and determine whether they improve therapeutic efficacy in naive and tumor-bearing mice. ..
  14. Identify and amplify T cell effector mechanisms
    Bernard Fox; Fiscal Year: 2001
    ..If this innovative approach using novel immune activated pro-drug molecules is successful in these preclinical studies it could be rapidly translated into phase I clinical trials for patients with cancer. ..
  15. MECHANISMS THAT REGULATE TUMOR SPECIFIC IMMUNE RESPONSES
    Bernard Fox; Fiscal Year: 2001
    ..3) To develop in vivo strategies that promote the differentiation of tumor-specific T1 T cells and determine whether they improve therapeutic efficacy in naive and tumor-bearing mice. ..
  16. MECHANISMS THAT REGULATE TUMOR SPECIFIC IMMUNE RESPONSES
    Bernard Fox; Fiscal Year: 2000
    ..3) To develop in vivo strategies that promote the differentiation of tumor-specific T1 T cells and determine whether they improve therapeutic efficacy in naive and tumor-bearing mice. ..
  17. MECHANISMS THAT REGULATE TUMOR SPECIFIC IMMUNE RESPONSES
    Bernard Fox; Fiscal Year: 1999
    ..3) To develop in vivo strategies that promote the differentiation of tumor-specific T1 T cells and determine whether they improve therapeutic efficacy in naive and tumor-bearing mice. ..